Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8446 to 8460 of 9042 results

  1. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  2. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

    Technology appraisal guidance
    Discontinued

  3. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Discontinued Reference number: GID-HST10022

    Highly specialised technologies guidance
    Discontinued

  6. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development Reference number: GID-TA10405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued

  8. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  9. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued Reference number: GID-TA10228

    Technology appraisal guidance
    Discontinued

  11. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  13. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued